FDA reiterates risks of antimalarial drug use for COVID-19, as study into efficacy ends early due to deaths

[ad_1]

FDA reiterates risks of antimalarial drug use for COVID-19, as study into efficacy ends early due to deaths

The U.S. Food and Drug Administration (FDA) has issued a new warning about the known side effects of hydroxychrloroquine and chloroquine, two antimalarial drugs (also used in the treatment of chronic rheumatoid arthritis and lupus), on the same day that a group of researchers published a paper in t….
[ad_2]

Source

admin

Recommended Posts

Why your business needs a website

June 30, 2021

7 reasons why content creation is important

November 19, 2020

Regulatory roadblocks are holding back Colombia’s tech and transportation industries

July 8, 2020